Systemic lupus erythematosus is a heterogeneous chronic inflammatory autoimmune disorder characterized by an exacerbated expression of cytokines and chemokines in different tissues and organs. Renal involvement is a significant contributor to the morbidity and mortality of systemic lupus erythematosus, and its diagnosis is based on renal biopsy, an invasive procedure with a high risk of complications. Therefore, the development of alternative, non-invasive diagnostic tests for kidney disease in patients with systemic lupus erythematosus is a priority.
Aim
To evaluate the plasma levels of a panel of cytokines and chemokines using multiplex xMAP technology in a cohort of Colombian patients with active and inactive systemic lupus erythematosus, and to evaluate their potential as biomarkers of renal involvement.
Results
Plasma from 40 systemic lupus erythematosus non-nephritis patients and 80 lupus nephritis patients with different levels of renal involvement were analyzed for 39 cytokines using Luminex xMAP technology. Lupus nephritis patients had significantly increased plasma eotaxin, TNF-α, interleukin-17-α, interleukin-10, and interleukin-15 as compared to the systemic lupus erythematosus non-nephritis group. Macrophage-derived chemokine, growth regulated oncogene alpha, and epidermal growth factor were significantly elevated in systemic lupus erythematosus non-nephritis patients when compared to lupus nephritis individuals. Plasma eotaxin levels allowed a discrimination between systemic lupus erythematosus non-nephritis and lupus nephritis patients, for which we performed a receiver operating characteristic curve to confirm. We observed a correlation of eotaxin levels with active nephritis (Systemic Lupus Erythematosus Disease Activity Index). Our data indicate that circulating cytokines and chemokines could be considered good predictors of renal involvement in individuals with systemic lupus erythematosus.
MohanCPuttermanC. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol2015; 11: 329–341.
2.
MoroniGQuagliniSRadiceA, et al.The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy. J Immunol Res2015; 2015: 1–8.
3.
WeeningJJD’AgatiVDSchwartzMM, et al.The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol JASN2004; 15: 241–250.
4.
MisraRGuptaR. Biomarkers in lupus nephritis. Int J Rheum Dis2015; 18: 219–232.
5.
MokCC. Biomarkers for lupus nephritis: A critical appraisal. J Biomed Biotechnol2010; 2010: 1–11.
6.
LiangMHSchurPHFortinP, et al.The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum2006; 54: 421–432.
7.
ChenTEstrellaMFineD. Predictors of kidney biopsy complication among patients with systemic lupus erythematosus. Lupus2012; 21: 848–854.
8.
AzoicăiTBelibouIMLozneanuL, et al.Large variability of the activity and chronicity indexes within and between histological classes of lupus nephritis. Rom J Morphol Embryol2017; 58: 73–78.
9.
DossusLBeckerSAchaintreD, et al.Validity of multiplex-based assays for cytokine measurements in serum and plasma from ‘non-diseased’ subjects: Comparison with ELISA. J Immunol Methods2009; 350: 125–132.
10.
ElshalMMccoyJ. Multiplex bead array assays: Performance evaluation and comparison of sensitivity to ELISA?Methods2006; 38: 317–323.
11.
LengSXMcElhaneyJEWalstonJD, et al.ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci2008; 63: 879–884.
YapDYHLaiKN. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol2010; 2010: 1–10.
14.
LichtmanEIHelfgottSMKriegelMA. Emerging therapies for systemic lupus erythematosus? Focus on targeting interferon-alpha. Clin Immunol2012; 143: 210–221.
LuJKwanBC-HLaiFM-M, et al.Gene expression of TWEAK/Fn14 and IP-10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis: Intra-renal gene expression in SLE. Nephrology2011; 16: 426–432.
18.
BlancoP. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science2001; 294: 1540–1543.
19.
BiesenRDemirCBarkhudarovaF, et al.Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum2008; 58: 1136–1145.
20.
ChengQMumtazIMKhodadadiL, et al.Autoantibodies from long-lived ‘memory’ plasma cells of NZB/W mice drive immune complex nephritis. Ann Rheum Dis2013; 72: 2011–2017.
21.
Navarro-QuirozEPacheco-LugoLLorenziH, et al.High-throughput sequencing reveals circulating miRNAs as potential biomarkers of kidney damage in patients with systemic lupus erythematosus. PLOS ONE2016; 11: e0166202–e0166202.
22.
WeaverCTHattonRD. Interplay between the TH17 and TReg cell lineages: A (co-)evolutionary perspective. Nat Rev Immunol2009; 9: 883–889.
23.
ElewaEAZakariaOMohamedEI, et al.The role of interleukins 4, 17 and interferon gamma as biomarkers in patients with systemic lupus erythematosus and their correlation with disease activity. Egypt Rheumatol2014; 36: 21–27.
24.
WongCKHoCYLiEK, et al.Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus2000; 9: 589–593.
25.
ZhaoX-FPanH-FYuanH, et al.Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep2010; 37: 81–85.
26.
Abdel GalilSMEzzeldinNEl-BoshyME. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine2015; 76: 280–287.
27.
PostalMAppenzellerS. The role of tumor necrosis factor-alpha (TNF-α) in the pathogenesis of systemic lupus erythematosus. Cytokine2011; 56: 537–543.
28.
GabayCCakirNMoralF, et al.Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol1997; 24: 303–308.
29.
SabryASheashaaHElhusseiniA, et al.Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: Its correlation with disease activity. Cytokine2006; 35: 148–153.
30.
Studnicka-BenkeASteinerGPeteraP, et al.Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol1996; 35: 1067–1074.
31.
GómezDCorreaPAGómezLM, et al.Th1/Th2 cytokines in patients with systemic lupus erythematosus: Is tumor necrosis factor alpha protective?Semin Arthritis Rheum2004; 33: 404–413.
32.
HooksJJMoutsopoulosHMGeisSA, et al.Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med1979; 301: 5–8.
33.
PrebleOTBlackRJFriedmanRM, et al.Systemic lupus erythematosus: Presence in human serum of an unusual acid-labile leukocyte interferon. Science1982; 216: 429–431.
34.
RönnblomLEAlmGVObergKE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med1990; 227: 207–210.
35.
KitauraMSuzukiNImaiT, et al.Molecular cloning of a novel human cc chemokine (eotaxin-3) that is a functional ligand of CC chemokine receptor 3. J Biol Chem1999; 274: 27975–27980.
36.
PaplińskaMHermanowicz-SalamonJNejman-GryzP, et al.Expression of eotaxins in the material from nasal brushing in asthma, allergic rhinitis and COPD patients. Cytokine2012; 60: 393–399.
37.
OwczarekWPaplińskaMTargowskiT, et al.Analysis of eotaxin 1/CCL11, eotaxin 2/CCL24 and eotaxin 3/CCL26 expression in lesional and non-lesional skin of patients with atopic dermatitis. Cytokine2010; 50: 181–185.
38.
WuDZhouJBiH, et al.CCL11 as a potential diagnostic marker for asthma?J Asthma2014; 51: 847–854.
39.
AdarTShteingartSBen Ya’acovA, et al.From airway inflammation to inflammatory bowel disease: Eotaxin-1, a key regulator of intestinal inflammation. Clin Immunol2014; 153: 199–208.
40.
Kokkonen H, Söderström I, Rocklöv J, et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010; 62(2): 383–391.
41.
ChaeS-CParkY-RShimS-C, et al.Eotaxin-3 gene polymorphisms are associated with rheumatoid arthritis in a Korean population. Hum Immunol2005; 66: 314–320.
42.
BanchereauRHongSCantarelB, et al.Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell2016; 165: 1548–1550.
43.
Menzies-GowAYingSSabroeI, et al.Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol2002; 169: 2712–2718.
44.
HuauxFGharaee-KermaniMLiuT, et al.Role of eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. Am J Pathol2005; 167: 1485–1496.
45.
HuberAKWangLHanP, et al.Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS. Neurology2014; 83: 1500–1507.
46.
LiaoXPirapakaranTLuoXM. Chemokines and chemokine receptors in the development of lupus nephritis. Mediators Inflamm2016; 2016: 1–15.
47.
RollinsBJ. Chemokines. Blood1997; 90: 909–928.
48.
RansohoffRM. Chemokines and chemokine receptors: Standing at the crossroads of immunobiology and neurobiology. Immunity2009; 31: 711–721.
49.
HanaokaHOkazakiYHashiguchiA, et al.Overexpression of CXCR4 on circulating B cells in patients with active systemic lupus erythematosus. Clin Exp Rheumatol2015; 33: 863–870.
50.
WorthmannKGuelerFvon VietinghoffS, et al.Pathogenetic role of glomerular CXCL13 expression in lupus nephritis: Glomerular CXCL13 expression in SLE. Clin Exp Immunol2014; 178: 20–27.
